GlobeNewswire·Apr 22, 2026, 7:00 AM ET

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

Jade Biosciences, Inc. appointed Edward R. Conner, M.D. as Chief Medical Officer effective April 22, 2026.
Dr. Conner joins Jade from Ardelyx, Inc., where he previously served as Chief Medical Officer.
His prior executive roles include CMO positions at Third Harmonic Bio, Locanabio, Audentes Therapeutics, and Sangamo Therapeutics, as well as a Medical Director role at Genentech.
As CMO, Dr. Conner will lead the clinical and medical organization to oversee development strategy and data generation for the company's autoimmune disease pipeline.
CEO Tom Frohlich highlighted Dr. Conner's expertise as instrumental for upcoming milestones, including interim Phase 1 data for JADE101, initiating a Phase 2 trial in IgA nephropathy, and advancing JADE201 and JADE301.
Jade also expanded Dr. Andrew King's role to President of R&D to reflect his strategic leadership across the research and development organization.
Dr. Conner holds an M.D. from the University of California, San Francisco, a residency from the University of Michigan, a fellowship from Johns Hopkins, and a B.S. in biology from Duke University.
Jade's pipeline includes JADE101 targeting the cytokine APRIL, JADE201 as an afucosylated anti-BAFF-R monoclonal antibody, and JADE301 as an undisclosed antibody candidate.
The company was launched based on assets licensed from Paragon Therapeutics.